AstraZeneca PLC (LON:AZN – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of £141.38 and traded as high as £145.66. AstraZeneca shares last traded at £144.56, with a volume of 649,606 shares traded.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on AZN shares. Citigroup lifted their price objective on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a research note on Friday, April 10th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and set a £115 target price on shares of AstraZeneca in a research note on Friday, June 26th. Finally, Jefferies Financial Group restated a “buy” rating and set a £180 target price on shares of AstraZeneca in a report on Friday, June 26th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of £153.33.
Get Our Latest Stock Report on AZN
AstraZeneca Stock Down 0.6%
AstraZeneca Company Profile
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Featured Articles
- Five stocks we like better than AstraZeneca
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
